Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$2.23
-5.1%		$3.30
$2.23
▼
$13.40
$1.46M1.121.08 million shs183,186 shs
Gelteq Limited stock logo
GELS
Gelteq
$0.90
+0.8%		$0.60
$0.39
▼
$2.02
$9.64M-0.417.10 million shs1.41 million shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.53
-1.9%		$0.51
$0.26
▼
$17.20
$6.95M0.5364,567 shs23,593 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.33
+0.4%		$1.25
$0.85
▼
$4.74
$6.32M1.31165,117 shs92,753 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-5.11%-34.41%-30.31%-27.83%-83.15%
Gelteq Limited stock logo
GELS
Gelteq
+0.76%+62.02%+59.55%+81.09%-19.64%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-1.85%+2.22%+17.78%-25.87%-94.24%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+0.38%+1.15%+17.26%+16.23%-71.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$2.23
-5.1%		$3.30
$2.23
▼
$13.40
$1.46M1.121.08 million shs183,186 shs
Gelteq Limited stock logo
GELS
Gelteq
$0.90
+0.8%		$0.60
$0.39
▼
$2.02
$9.64M-0.417.10 million shs1.41 million shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.53
-1.9%		$0.51
$0.26
▼
$17.20
$6.95M0.5364,567 shs23,593 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.33
+0.4%		$1.25
$0.85
▼
$4.74
$6.32M1.31165,117 shs92,753 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-5.11%-34.41%-30.31%-27.83%-83.15%
Gelteq Limited stock logo
GELS
Gelteq
+0.76%+62.02%+59.55%+81.09%-19.64%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-1.85%+2.22%+17.78%-25.87%-94.24%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+0.38%+1.15%+17.26%+16.23%-71.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
2.67
Moderate Buy$44.001,873.09% Upside
Gelteq Limited stock logo
GELS
Gelteq
1.00
SellN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.33
Hold$75.0014,050.94% Upside
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CANF, GELS, RVPH, and SNOA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/7/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/24/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/2/2026
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00 ➝ $8.00
6/26/2026
Gelteq Limited stock logo
GELS
Gelteq
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/11/2026
Gelteq Limited stock logo
GELS
Gelteq
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$405K3.61N/AN/A$1.76 per share1.27
Gelteq Limited stock logo
GELS
Gelteq
$165.65K58.20N/AN/A$1.08 per share0.83
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$1.48 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$19.53M0.32N/AN/A$1.38 per share0.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$22.80N/AN/AN/AN/AN/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
-$4.30MN/AN/AN/AN/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$19.86M-$1.85N/AN/AN/AN/A-391.58%-119.08%11/12/2026 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.17M-$1.22N/AN/AN/A-10.33%-21.41%-6.08%11/16/2026 (Estimated)

Latest CANF, GELS, RVPH, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.3850-$0.19+$0.1950N/AN/AN/A
8/6/2026Q1 2027
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.30$0.02+$0.32-$0.09$4.99 million$6.41 million
6/30/2026Q2 2026
Gelteq Limited stock logo
GELS
Gelteq
N/A-$0.12N/A-$0.12N/AN/A
6/16/2026Q4 2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.24-$0.33-$0.09-$0.33$5.57 million$5.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
Gelteq Limited stock logo
GELS
Gelteq
N/A
0.09
N/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
2.08
2.08
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.99
2.29

Institutional Ownership

CompanyInstitutional Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
21.00%
Gelteq Limited stock logo
GELS
Gelteq
N/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.80%
Gelteq Limited stock logo
GELS
Gelteq
N/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
8.90%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
8655,000N/ANot Optionable
Gelteq Limited stock logo
GELS
Gelteq
N/A10.71 millionN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
513.11 million11.67 millionOptionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1804.79 million4.74 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting
August 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sonoma-pharmaceuticals-cancels-adjourned-special-stockholder-meeting?utm_source=marketbeat.com&utm_medium=referral
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
August 6, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue
August 6, 2026  |  benzinga.comhttps://www.benzinga.com/markets/earnings/26/08/60993290/sonoma-pharmaceuticals-turns-ebitda-positive-for-first-time-with-record-quarterly-revenue?utm_source=snapi
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
June 30, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity
June 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sonoma-pharmaceuticals-expands-at-the-market-equity-offering-capacity?utm_source=marketbeat.com&utm_medium=referral
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
June 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68784561-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2026-financial-results-200.htm
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
June 16, 2026  |  accessnewswire.comA
What's going on with Sonoma Pharma stock Monday?
April 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/what-s-going-on-with-sonoma-pharma-stock-monday/ar-AA21PdPx
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
April 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/sonoma-pharmaceuticals-announces-pricing-4-132100121.html
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
March 24, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68022819-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-announces-u-s-retail-launch-of-advanced-burn-relief-hydrogel-in-cvs-and-walmart-200.htm
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
March 24, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey’s Aquanil Brand for Sensitive Skin
March 18, 2026  |  freep.comF
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin
March 18, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
February 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67666437-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-reports-third-fiscal-quarter-2026-financial-results-200.htm
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
February 10, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
January 29, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67552599-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-welcomes-new-member-of-its-board-of-directors-and-new-senior-vice-president-of-regulatory-qualit-200.htm
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
January 28, 2026  |  accessnewswire.comA
Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
November 14, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-11/66971748-sonoma-pharmaceuticals-inc-national-rosacea-society-awards-seal-of-acceptance-to-sonoma-pharmaceuticals-for-reliefacyn-advanced-200.htm
Sonoma Pharmaceuticals’ Reliefacyn Advanced receives NRS Seal of Acceptance
November 13, 2025  |  msn.comhttps://www.msn.com/en-us/health/diseases-and-conditions/sonoma-pharmaceuticals-reliefacyn-advanced-receives-nrs-seal-of-acceptance/ar-AA1QnZQ4
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
November 13, 2025  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$2.23 -0.12 (-5.11%)
As of 09/4/2026 04:00 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Gelteq stock logo

Gelteq NASDAQ:GELS

$0.90 +0.01 (+0.76%)
As of 09/4/2026 04:00 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.53 -0.01 (-1.85%)
As of 09/4/2026 03:48 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.32 +0.01 (+0.38%)
As of 09/4/2026 04:00 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas